| Literature DB >> 17971820 |
D T O'Hagan1, A Wack, A Podda.
Abstract
The MF59 adjuvant has been included in a licensed influenza vaccine for a decade. Hence, we have a significant amount of clinical data to establish its potency and safety. We can now reassess our early preclinical studies and determine whether or not they were useful to predict human responses. The main lesson learned is that mouse models can be valuable, but one must ask the right questions and the models must be used appropriately.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17971820 DOI： 10.1038/sj.clpt.6100402
Source DB: PubMed Journal: Clin Pharmacol Ther ISSN： 0009-9236 Impact factor: 6.875